35.63
price up icon0.11%   0.04
after-market アフターアワーズ: 35.50 -0.13 -0.36%
loading
前日終値:
$35.59
開ける:
$35.86
24時間の取引高:
3.78M
Relative Volume:
2.57
時価総額:
$5.63B
収益:
$803.07M
当期純損益:
$-358.81M
株価収益率:
-12.41
EPS:
-2.87
ネットキャッシュフロー:
$-374.21M
1週間 パフォーマンス:
-2.68%
1か月 パフォーマンス:
+0.65%
6か月 パフォーマンス:
-12.69%
1年 パフォーマンス:
-26.28%
1日の値動き範囲:
Value
$35.05
$36.40
1週間の範囲:
Value
$35.05
$38.90
52週間の値動き範囲:
Value
$33.33
$54.44

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1176)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
927
Name
Twitter
@ionispharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

IONS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
35.63 5.63B 803.07M -358.81M -374.21M -2.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
Dec 20, 2024

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis gets FDA approval for Tryngolza - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis notches Arrowhead win; Tryngolza cleared for FCS - BioWorld Online

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis To Get Head Start On Arrowhead With Tryngzola Launch - Citeline News & Insights

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis gets a milestone approval; Another top FDA official to step down - BioPharma Dive

Dec 20, 2024
pulisher
Dec 20, 2024

FDA approves Ionis’ TRYNGOLZA for FCS treatment - Yahoo Finance

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis Pharmaceuticals (NASDAQ:IONS) Given "Buy" Rating at Needham & Company LLC - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Outperform" Rating from William Blair - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

FDA approves Ionis’ Tryngolza - The Pharma Letter

Dec 20, 2024
pulisher
Dec 20, 2024

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood - Yahoo Finance UK

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome - BioSpace

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis stock rises following FDA approval of TRYNGOLZA By Investing.com - Investing.com Canada

Dec 20, 2024
pulisher
Dec 20, 2024

Ionis stock rises following FDA approval of TRYNGOLZA - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

FDA Approves Ionis Pharmaceuticals' (IONS) First Fully Owned Dru - GuruFocus.com

Dec 20, 2024
pulisher
Dec 19, 2024

Olezarsen Earns First-Ever FDA Approval for Familial Chylomicronemia Syndrome - MD Magazine

Dec 19, 2024
pulisher
Dec 19, 2024

Ionis Secures Historic FDA Approval for First-Ever FCS Treatment, TRYNGOLZA Shows 57% Triglyceride Reduction - StockTitan

Dec 19, 2024
pulisher
Dec 19, 2024

US FDA approves Ionis Pharma's genetic disorder drug - Reuters

Dec 19, 2024
pulisher
Dec 19, 2024

Ionis wins FDA approval for a rare disease therapy that lowers triglycerides - STAT

Dec 19, 2024
pulisher
Dec 19, 2024

Ionis to hold third quarter 2024 financial results webcast - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 19, 2024

RNAi Technology Market to Witness Huge Growth by 2031 | Alnylam - openPR

Dec 19, 2024
pulisher
Dec 19, 2024

Geode Capital Management LLC Increases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Dec 19, 2024
pulisher
Dec 17, 2024

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Update - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR

Dec 16, 2024
pulisher
Dec 16, 2024

Ionis Pharmaceuticals, Inc. announced that it expects to receive $624.972654 million in funding from Biogen Inc. - Marketscreener.com

Dec 16, 2024
pulisher
Dec 15, 2024

Trend Tracker for (IONS) - Stock Traders Daily

Dec 15, 2024
pulisher
Dec 14, 2024

Y Intercept Hong Kong Ltd Acquires Shares of 20,141 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Stifel Financial Corp - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

CMS Tells MA Plans Not To Exclude Biogen’s Qalsody Because Of Accelerated Approval - Citeline

Dec 13, 2024
pulisher
Dec 13, 2024

XTX Topco Ltd Takes $673,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Dec 13, 2024
pulisher
Dec 12, 2024

How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% - MSN

Dec 12, 2024
pulisher
Dec 12, 2024

Theratechnologies Secures Canadian Rights for Ionis RNA Medicines - TipRanks

Dec 12, 2024
pulisher
Dec 11, 2024

Ionis to present at upcoming investor conferences - Longview News-Journal

Dec 11, 2024
pulisher
Dec 10, 2024

Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year By Investing.com - Investing.com Nigeria

Dec 10, 2024
pulisher
Dec 10, 2024

Transthyretin Amyloid Cardiomyopathy Market: Size, Share, - openPR

Dec 10, 2024
pulisher
Dec 10, 2024

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease - The Eastern Progress Online

Dec 10, 2024
pulisher
Dec 10, 2024

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Groupama Asset Managment - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Ionis announces proposed public offering of common stock - The Eastern Progress Online

Dec 09, 2024
pulisher
Dec 09, 2024

FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More - BioSpace

Dec 09, 2024
pulisher
Dec 08, 2024

Narrow-Moat Ionis Is Expanding Its Neurology and Cardiology Portfolio to Strengthen Its Moat - Morningstar

Dec 08, 2024
pulisher
Dec 07, 2024

Ionis announces pricing of $500.3 million public offering - The Eastern Progress Online

Dec 07, 2024
pulisher
Dec 07, 2024

Ionis Pharmaceuticals : announces appointment of Brett P. Monia Ph.D. to its board of directors - Marketscreener.com

Dec 07, 2024
pulisher
Dec 07, 2024

Ionis Pharmaceuticals : to Provide Corporate Update at 2019 Annual Meeting of Stockholders - Marketscreener.com

Dec 07, 2024
pulisher
Dec 07, 2024

Ionis Pharmaceuticals : Provides Corporate Update at 2018 Annual Meeting of Stockholders - Marketscreener.com

Dec 07, 2024
pulisher
Dec 06, 2024

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Dec 06, 2024
pulisher
Dec 05, 2024

Theratechnologies expands rare disease portfolio with Ionis partnership - MSN

Dec 05, 2024
pulisher
Dec 05, 2024

Company plans to seek Canada OK of HAE treatment donidalorsen - Angioedema News Today

Dec 05, 2024
pulisher
Dec 05, 2024

Theratechnologies enters exclusive licensing agreement with Ionis - Yahoo Finance

Dec 05, 2024
pulisher
Dec 04, 2024

Theratechnologies expands rare disease portfolio with Ionis partnership | 2024-12-04 | Investing News - Stockhouse Publishing

Dec 04, 2024
pulisher
Dec 04, 2024

Theratechnologies Expands Portfolio with Ionis Deal - TipRanks

Dec 04, 2024

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ionis Pharmaceuticals Inc (IONS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Monia Brett P
Chief Executive Officer
Nov 12 '24
Sale
38.05
6,630
252,294
167,393
LOSCALZO JOSEPH
Director
Nov 12 '24
Sale
37.86
13,508
511,426
32,251
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):